Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Mise à jour : Il y a 4 ans
Référence : NCT00563836

Femme Homme

Extrait

Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after tumor resection.


Critère d'inclusion

  • Ovarian Cancer ,Epithelial Ovarian Cancer

Liens